Holen Sie sich die Stockscreener-App
0.5159
0.92%
-0.0101
Schlusskurs vom Vortag:
$0.526
Offen:
$0.54
24-Stunden-Volumen:
55,306
Relative Volume:
0.17
Marktkapitalisierung:
$78.68M
Einnahmen:
$49.09M
Nettoeinkommen (Verlust:
$-52.15M
KGV:
-0.7937
EPS:
-0.65
Netto-Cashflow:
$-45.93M
1W Leistung:
-3.31%
1M Leistung:
-16.97%
6M Leistung:
-59.91%
1J Leistung:
-60.22%
1-Tages-Spanne:
$0.513
$0.58
1-Wochen-Bereich:
$0.5105
$0.5995
52-Wochen-Spanne:
$0.45
$2.04
Biodesix Inc Stock (BDSX) Company Profile
Firmenname
Biodesix Inc
Sektor
Branche
Telefon
303-417-0500
Adresse
919 WEST DILLON ROAD, LOUISVILLE
Vergleichen Sie BDSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.5159 | 78.68M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
424.48 | 160.15B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.06 | 141.09B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
470.05 | 35.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.06 | 30.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.56 | 26.50B | 15.41B | 1.37B | 2.11B | 7.50 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-26 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-13 | Eingeleitet | TD Cowen | Buy |
| 2024-05-03 | Eingeleitet | Lake Street | Buy |
| 2021-11-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | Eingeleitet | BTIG Research | Buy |
| 2020-11-23 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-23 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Biodesix Inc Aktie (BDSX) Neueste Nachrichten
Biodesix, Inc. (NASDAQ:BDSX) Receives $2.95 Average Target Price from Analysts - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Geode Capital Management LLC Increases Position in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Canaccord Genuity Group Lowers Biodesix (NASDAQ:BDSX) Price Target to $2.50 - Defense World
Biodesix (BDSX) Target Price Reduced by Canaccord Amid Market Ch - GuruFocus
Wells Fargo & Company MN Has $1.28 Million Holdings in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix to Report First Quarter 2025 Financial Results on May 1 - GuruFocus
Biodesix, Inc. to Release First Quarter 2025 Financial Results on May 13 - Nasdaq
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - Bluefield Daily Telegraph
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewswire Inc.
Biodesix and Bio-Rad Drive Advances in ctDNA-Based Cancer Therapies - Technology Networks
Ratios Uncovered: Breaking Down Biodesix Inc (BDSX)’s Trailing Twelve Months Metrics - DWinneX
Silverarc Capital Management LLC Acquires 771,187 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix Inc (BDSX) Stock: From Low to High in 52 Weeks - investchronicle.com
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types - MSN
Biodesix Inc [BDSX] Chief Accounting Officer makes an insider purchase of 3,630 shares worth 3355.0. - knoxdaily.com
Biodesix and Bio-Rad publish data linking ctDNA changes to treatment outcomes in solid tumors - Select Science
Is Biodesix Inc (BDSX) worth investing in despite its overvalued state? - uspostnews.com
Market Resilience: Biodesix Inc (BDSX) Finishes Weak at 0.49, Down -2.00 - DWinneX
Biodesix partner, Friends of Cancer Research, publishes data in - GuruFocus
Biodesix and Bio-Rad Laboratories Collaborate on Research Revealing ctDNA's Role in Cancer Treatment Outcomes - Nasdaq
Biodesix partner, Friends of Cancer Research, publishes - GlobeNewswire
Major Clinical Trial Proves ctDNA Testing Accurately Predicts Cancer Treatment Outcomes in Breakthrough Study - Stock Titan
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding - simplywall.st
Biodesix Announces Board Member Resignations - TipRanks
Biodesix, Inc. Announces Director and Committee Resignations - marketscreener.com
Samjo Management LLC Makes New Investment in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix Inc [BDSX] stock was sold by Vazquez Chris at the price of US$3355.0 - knoxdaily.com
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.5% in March - MarketBeat
HighTower Advisors LLC Acquires 22,500 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World
AIGH Capital Management LLC Buys 500,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Closing Figures Unveiled: Biodesix Inc (BDSX) Drop -3.06, Closes at 0.61 - DWinneX
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
BDSX stock touches 52-week low at $0.63 amid market challenges - Investing.com
Perkins Capital Management Inc. Purchases 335,429 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update - MarketBeat
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier - Business Wire
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 24.6% in February - Defense World
Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference - Business Wire
Biodesix chief commercial officer sells shares worth $16,198 - MSN
Q1 Earnings Estimate for Biodesix Issued By William Blair - MarketBeat
Biodesix's (BDSX) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
Biodesix (NASDAQ:BDSX) Issues Quarterly Earnings Results - MarketBeat
Finanzdaten der Biodesix Inc-Aktie (BDSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biodesix Inc-Aktie (BDSX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pestano Gary Anthony | Chief Development Officer |
Feb 11 '25 |
Sale |
0.92 |
16,748 |
15,479 |
156,008 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 11 '25 |
Sale |
0.92 |
17,527 |
16,198 |
128,039 |
| Hutton Scott | President & CEO |
Feb 11 '25 |
Sale |
0.92 |
83,660 |
77,319 |
701,947 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 11 '25 |
Sale |
0.92 |
24,664 |
22,794 |
246,460 |
1.65%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):